Inari Medical (NARI) Stock Price, News & Analysis

Company Overview

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $79.97 to $79.97
• 50-Day Range: $79.97 to $79.97
• 52-Week Range: $39.76 to $79.99
• Volume: N/A
• Average Volume: 1.49 million shs
• Market Capitalization: $4.68 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $69.22
• Consensus Rating: Hold

Inari Medical Stock Analysis - MarketRank™

Inari Medical scored higher than 6% of companies evaluated by MarketBeat, and ranked 907th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Inari Medical has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 2 buy ratings, 12 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Inari Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inari Medical are expected to grow in the coming year, from ($0.82) to $0.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inari Medical is -59.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inari Medical is -59.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inari Medical has a P/B Ratio of 9.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NARI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inari Medical does not currently pay a dividend.

Dividend Growth

Inari Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NARI.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Inari Medical this week, compared to 4 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inari Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.60% of the stock of Inari Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.98% of the stock of Inari Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NARI Stock Analysis - Frequently Asked Questions

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) released its earnings results on Wednesday, February, 28th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.09. The company's quarterly revenue was up 22.5% on a year-over-year basis.
Read the conference call transcript.

When did Inari Medical IPO?

Inari Medical (NARI) raised $110 million in an initial public offering (IPO) on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inari Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 2/28/2024
• Today: 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NARI
• CIK: 1531048
• Web: www.inarimedical.com
• Phone: 877-923-4747
• Fax: N/A
• Employees: 800
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Inari Medical: $69.22
• High Price Target: $80.00
• Low Price Target: $47.00
• Potential Upside/Downside: -13.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.64 million
• Net Margins: -13.68%
• Pretax Margin: -9.29%
• Return on Equity: -10.09%
• Return on Assets: -6.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $493.63 million
• Price / Sales: 9.48
• Cash Flow: $0.09 per share
• Price / Cash Flow: 906.95
• Book Value: $8.07 per share
• Price / Book: 9.91

Miscellaneous

• Outstanding Shares: 58,540,000
• Free Float: 52,338,000
• Market Cap: $4.68 billion
• Optionable: Optionable
• Beta: 1.02